Zoetis Revenue 2011-2021 | ZTS

Zoetis annual/quarterly revenue history and growth rate from 2011 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Zoetis revenue for the quarter ending September 30, 2021 was $1.990B, a 11.42% increase year-over-year.
  • Zoetis revenue for the twelve months ending September 30, 2021 was $7.616B, a 16.42% increase year-over-year.
  • Zoetis annual revenue for 2020 was $6.675B, a 6.63% increase from 2019.
  • Zoetis annual revenue for 2019 was $6.26B, a 7.47% increase from 2018.
  • Zoetis annual revenue for 2018 was $5.825B, a 9.76% increase from 2017.
Zoetis Annual Revenue
(Millions of US $)
2020 $6,675
2019 $6,260
2018 $5,825
2017 $5,307
2016 $4,888
2015 $4,765
2014 $4,785
2013 $4,561
2012 $4,336
2011 $4,233
2010 $3,582
Zoetis Quarterly Revenue
(Millions of US $)
2021-09-30 $1,990
2021-06-30 $1,948
2021-03-31 $1,871
2020-12-31 $1,807
2020-09-30 $1,786
2020-06-30 $1,548
2020-03-31 $1,534
2019-12-31 $1,674
2019-09-30 $1,584
2019-06-30 $1,547
2019-03-31 $1,455
2018-12-31 $1,564
2018-09-30 $1,480
2018-06-30 $1,415
2018-03-31 $1,366
2017-12-31 $1,460
2017-09-30 $1,347
2017-06-30 $1,269
2017-03-31 $1,231
2016-12-31 $1,277
2016-09-30 $1,241
2016-06-30 $1,208
2016-03-31 $1,162
2015-12-31 $1,274
2015-09-30 $1,214
2015-06-30 $1,175
2015-03-31 $1,102
2014-12-31 $1,320
2014-09-30 $1,210
2014-06-30 $1,158
2014-03-31 $1,097
2013-12-31 $1,254
2013-09-30 $1,103
2013-06-30 $1,114
2013-03-31 $1,090
2012-12-31 $1,176
2012-09-30 $1,019
2012-06-30 $1,094
2012-03-31 $1,047
2011-12-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $106.785B $6.675B
Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.
Stock Name Country Market Cap PE Ratio
Takeda Pharmaceutical (TAK) Japan $43.860B 7.18
Catalent (CTLT) United States $21.140B 40.22
Stevanato Group S.p.A (STVN) Italy $6.778B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.022B 15.73
USANA Health Sciences (USNA) United States $1.957B 15.35
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.278B 5.89
Rafael Holdings (RFL) United States $0.124B 0.00
Lannett Co Inc (LCI) United States $0.089B 0.00